PetVivo Holdings, Inc. added Josh Ruben to its board of directors. Ruben, Managing Director of Life Sciences at Trinity Capital, brings 12 years of investment‑banking experience, including a role as Head of Life Science Tools and Diagnostics coverage at RBC Capital Markets.
Ruben holds a B.A. in Economics from Pomona College and an MBA from Harvard Business School. He has led multi‑billion‑dollar M&A and capital transactions in the life‑sciences sector and has a strong track record of evaluating and financing life‑science companies.
PetVivo CEO John Lai welcomed Ruben to the board, noting that his expertise will help guide the company’s expansion and value creation. Ruben said, “I am excited to join PetVivo and help accelerate the development of Spryng and explore new opportunities in the human therapeutic space.”
PetVivo’s board now has nine directors, with Ruben filling a vacancy left by the departure of former director. The appointment underscores the company’s focus on leveraging human‑health science to advance its Spryng® platform and other product pipeline.
Spryng® is a naturally derived, drug‑free injectable medical device that uses collagen and elastin to support joint health in companion animals. Ruben’s experience in capital strategy is expected to strengthen PetVivo’s growth in both veterinary and emerging human therapeutic markets.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.